Design Therapeutics (DSGN) Stock News

Design Therapeutics (NASDAQ:DSGN) reported progress in its GeneTAC® programs and Q2 2025 financial results. The company announced encouraging early pharmacokinetics data for DT-216P2 in Friedreich Ataxia (FA), showing favorable translation from non-human primates to humans via both intravenous and subcutaneous administration.

Key developments include the ongoing RESTORE-FA Phase 1/2 trial of DT-216P2 outside the US, while addressing an FDA clinical hold notice. The company also initiated a Phase 2 biomarker trial for DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) patients. Design reported $216.3 million in cash and securities, with a Q2 net loss of $19.1 million.

[ "Favorable pharmacokinetics data translation from non-human primates to humans for DT-216P2", "DT-216P2 showed improved exposure and PK parameters compared to previous formulation", "Strong cash position of $216.3 million to support pipeline development", "Advancement of multiple clinical programs including FA and FECD treatments" ]

Design Therapeutics announced the dosing of its first Friedreich ataxia (FA) patient in the RESTORE-FA Phase 1/2 multiple-ascending dose trial of DT-216P2 in Australia. The trial aims to evaluate safety, tolerability, and pharmacokinetics of the drug administered through IV and subcutaneous routes. Initial data from the ongoing Phase 1 single-ascending dose trial in healthy volunteers showed favorable safety and improved exposure compared to the first-generation formulation, with no injection site thrombophlebitis reported. However, the company's IND application to expand the trial to U.S. sites has been placed on clinical hold by the FDA due to nonclinical deficiencies. Design expects to report data from the MAD trial, including frataxin expression levels after 12 weeks of dosing, in 2026.

Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days after the event.

Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2025 RBC Capital Markets Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. Investors and interested parties can access the live webcast through the company's website at www.designtx.com, where it will remain archived for at least 30 days after the presentation.

Design Therapeutics (NASDAQ: DSGN) reported progress in Q1 2025 across its GeneTAC® programs and financial results. The company's Phase 1 trial for DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) showed favorable results, with the treatment being well-tolerated and no adverse events reported. A Phase 2 biomarker trial is planned for H2 2025. The ongoing Phase 1 SAD trial of DT-216P2 for Friedreich Ataxia (FA) continues, with plans to initiate a Phase 1/2 MAD patient study in mid-2025. The company appointed Chris Storgard, M.D. as Chief Medical Officer. Financially, Design reported a net loss of $17.7 million for Q1 2025, with R&D expenses at $15.4 million and G&A expenses at $5.0 million. The company maintains a strong cash position of $229.7 million, expected to fund operations into 2029.

Design Therapeutics (DSGN) reported positive Phase 1 data for DT-168, an eye drop treatment for Fuchs Endothelial Corneal Dystrophy (FECD). The Phase 1 SAD/MAD trial in 24 healthy volunteers demonstrated that DT-168 was well-tolerated with no serious adverse events, no ocular adverse events, and no treatment discontinuations. The GeneTAC® small molecule is designed to reduce mutant TCF4 gene expression causing corneal endothelial cell dysfunction. The company plans to advance to a Phase 2 biomarker trial in FECD patients in H2 2025, with data expected in 2026. The Phase 2 trial will evaluate safety, tolerability, and corneal endothelium biomarkers in patients scheduled for corneal transplant surgery, who will receive 0.5% DT-168 eye drops twice daily for approximately 4 weeks before surgery.

Design Therapeutics (DSGN) announced it will present Phase 1 safety data for its DT-168 program at Eyecelerator @ Park City 2025 on May 2, 2025. The presentation will cover findings from single- and multiple-ascending dose trials in healthy adult volunteers and outline Phase 2 development plans for Fuchs endothelial corneal dystrophy (FECD) patients.

DT-168 is a GeneTAC® small molecule delivered as an eye drop, designed to target CTG repeat expansion in the TCF4 gene and reduce mutant gene product expression that causes corneal endothelial cell dysfunction in FECD. The company aims to develop the first disease-modifying treatment for FECD, a progressive corneal disease that currently often requires corneal transplant surgery.

Design Therapeutics (DSGN) has appointed Chris M. Storgard, M.D. as Chief Medical Officer. Dr. Storgard brings over 20 years of drug development leadership experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals.

Prior to joining Design, Dr. Storgard served as CMO at ADARx Pharmaceuticals, Heron Therapeutics, and Fate Therapeutics. At Ardea Biosciences (an AstraZeneca Company), he led the global clinical program for lesinurad, achieving regulatory approvals in the US and Europe. His career includes roles at Biogen Idec, Amgen, Mayo Clinic, Scripps Mercy Hospital, and The Scripps Research Institute.

Design Therapeutics is advancing its portfolio of GeneTAC® small molecules, including DT-216P2 for Friedreich ataxia, focusing on treatments for serious degenerative genetic diseases.

Design Therapeutics (DSGN) has reported significant progress in its GeneTAC® programs and financial results for Q4 and full year 2024. The company has initiated a Phase 1 Single Ascending Dose trial of DT-216P2 in healthy volunteers for Friedreich Ataxia (FA), with patient dosing planned for mid-2025. Dosing is complete in the DT-168 Phase 1 healthy volunteer trial for Fuchs Endothelial Corneal Dystrophy (FECD), with data expected in H1 2025.

The company has achieved its enrollment target for the FECD observational study with 250 patients. Additionally, Design expects to select a development candidate for Myotonic Dystrophy Type-1 (DM1) in 2025.

Financial highlights include:

• R&D expenses: $12.2M for Q4 2024, $44.4M for full year
• G&A expenses: $4.5M for Q4 2024, $18.0M for full year
• Net loss: $13.7M for Q4 2024, $49.6M for full year
• Cash position: $245.5M as of December 31, 2024